Gyre Therapeutics, Inc. GYRE Ratios & Valuation
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Profitability | |||||
| Gross margin | 95.4%-1.0pp | 96.3%+0.4pp | 95.9%— | —— | |
| Operating margin | 9.9%-5.4pp | 15.3%+74.5pp | -59.3%— | —— | |
| Returns | |||||
| Return on invested capital | 12.8%— | —— | —— | —— | |
| Efficiency | |||||
| Asset turnover | 0.8×-0.1× | 0.9×-0.3× | 1.1×— | —— | |
| Liquidity | |||||
| Current ratio | 5.6×+2.3× | 3.3×+0.5× | 2.9×-1.2× | 4.1×+0.4× | |
| Leverage | |||||
| Debt-to-equity | 0×0.0× | 0×— | —— | 0×-0.1× | |
| Net debt / EBITDA | -2.6×-2.0× | -0.6×— | —— | —— | |
| Per Share | |||||
| Book value per share | $1.03+66.0% | $0.62+357% | -$0.24-143% | $0.56-58.1% | |
| Valuation | |||||
| Market capitalization | $694.58M-4.7% | $1.04B-47.2% | $1.97B— | —— | |
| Price / sales | 5.9×-1.3× | 9.8×-7.5× | 17.3×— | —— | |
| Price / book | 6.9×-3.8× | 16.4×— | —— | —— | |
| EV / EBITDA | 265.6×+206× | 58.1×— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Gyre Therapeutics, Inc.'s profit margins?
- Gyre Therapeutics, Inc. (GYRE) runs a 95.1% gross margin and a -0.1% operating margin, with a 6.3% net margin.
- Where do Gyre Therapeutics, Inc.'s ratios come from?
- Every ratio is computed from Gyre Therapeutics, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
